Showing results (421-430 of 794) with videos related to
Sort By:
Pageof 80
Clinical Pharmacokinetics|October 7, 2017
Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple MyelomaXiaoyu Yan, Pamela L Clemens, Thomas Puchalski, et al.Bone Marrow Transplantation|October 6, 2022
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myelomaCharalampos Charalampous, Utkarsh Goel, Morie Gertz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significanceShaji Kumar, S Vincent Rajkumar, Robert A Kyle, et al.BMC Cancer|April 29, 2024
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myelomaMeletios Dimopoulos, Pieter Sonneveld, Salomon Manier, et al.Clinical Lymphoma, Myeloma & Leukemia|May 11, 2015
Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo ClinicMuhammad A Mir, Prashant Kapoor, Shaji Kumar, et al.Mayo Clinic Proceedings|March 5, 2008
Serum uric acid: novel prognostic factor in primary systemic amyloidosisShaji Kumar, Angela Dispenzieri, Martha Q Lacy, et al.Leukemia|April 22, 2026
Gene expression-based dissemination score predicts early spread and poor outcomes in multiple myelomaArwa Bohra, Surendra Dasari, Saurabh Zanwar, et al.British Journal of Haematology|November 20, 2002
Bone marrow angiogenesis in multiple myeloma: effect of therapyShaji Kumar, Rafael Fonseca, Angela Dispenzieri, et al.Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 15, 2022
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working groupAshutosh D Wechalekar, M Teresa Cibeira, Simon D Gibbs, et al.Cancer|July 27, 2021
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.Pageof 80